A new lipid-based oral delivery system of Erythromycin (cas 114-07-8) for prolong sustain release activity
-
Add time:08/29/2019 Source:sciencedirect.com
Erythromycin (cas 114-07-8)-loaded solid lipid microparticles (SLM) based on solidified reverse micellar solution (SRMS) as an oral delivery formulation was studied. Hot homogenization technique was employed to prepare erythromycin stearate-loaded SLMs using blends of Softisan® 154 and Phospholipon® 90H or beeswax in the ratio of 1:2, and characterized in vitro. Antibacterial evaluation of the formulations was carried out by agar diffusion technique against some selected clinical isolates of bacterial. Preliminary pharmacokinetic study was performed after oral administration in male Albino rats. The results of matrix contain Softisan® 154 and phospholipon® 90H (1:2) showed that erythromycin-loaded SLM was smooth; particle size ranged from 10.3 ± 11.24 μm to 18.1 ± 10.11 μm and maximum encapsulation efficiency and loading capacity were 95.11 ± 0.3% and 43.22 ± 0.1 mg, respectively. While that of beeswax- containing matrix showed maximum particle size of 18.9 ± 21.10 μm, maximum encapsulation efficiency of 89.01 ± 0.11% and loading capacity of 39.02 ± 0.12 mg. All the formulations had prolonged release and antibacterial activity. Significantly (p > 0.05), prolonged plasma erythromycin concentration was obtained in the optimized formulation (>14 h) compared with commercial sample of erythromycin tablet (10h). Erythromycin stearate-loaded SLMs formulation could serve as an alternative to conventional oral formulation of erythromycin.
We also recommend Trading Suppliers and Manufacturers of Erythromycin (cas 114-07-8). Pls Click Website Link as below: cas 114-07-8 suppliers
Prev:Erythromycin (cas 114-07-8) relaxes BALB/c mouse airway smooth muscle
Next:Isooctane-based anionic and zwitterionic surfactant: Synergistic interaction of mixed reverse micelle and solubilisation of Erythromycin (cas 114-07-8)) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Isooctane-based anionic and zwitterionic surfactant: Synergistic interaction of mixed reverse micelle and solubilisation of Erythromycin (cas 114-07-8)08/30/2019
- Erythromycin (cas 114-07-8) relaxes BALB/c mouse airway smooth muscle08/28/2019
- Bioinspired Pt-free molecularly imprinted hydrogel-based magnetic Janus micromotors for temperature-responsive recognition and adsorption of Erythromycin (cas 114-07-8) in water08/27/2019
- Inhibitory effects of dissolved organic matter on Erythromycin (cas 114-07-8) bioavailability and possible mechanisms08/26/2019
- Original ResearchObstetricsAzithromycin vs Erythromycin (cas 114-07-8) for the management of preterm premature rupture of membranes08/25/2019
- Erythromycin (cas 114-07-8) degradation and ERY-resistant gene inactivation in Erythromycin (cas 114-07-8) mycelial dreg by heat-activated persulfate oxidation08/24/2019
- Erythromycin (cas 114-07-8) acts through the ghrelin receptor to attenuate inflammatory responses in chondrocytes and maintain joint integrity08/23/2019
- Partitioning isotherm and kinetic of Erythromycin (cas 114-07-8) into mixed reverse micelle during forward transfer08/22/2019
- Synthesis of the Erythromycin (cas 114-07-8)-conjugated nanodendrimer and its antibacterial activity08/21/2019
-
Health and Chemical more >